Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HHS vs TTI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HHS Captures Overall Composite Edge (61.8 BUY vs 35.2 SELL), While TTI Leads 4–1 on Growth & Valuation Pillars

HHS Overall Winner 6-Pillar Tally: HHS 1 – 4 TTI (1 Tie) Matrix Metrics: HHS 5 – 5 TTI

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) captures the overall head-to-head institutional edge over TETRA Technologies, Inc. (TTI) on higher Unified Composite conviction (61.8/100 BUY vs. 35.2/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while TTI wins 4–1 across the 6-pillar growth and valuation breakdown. HHS trades at $3.84 (14.3x Forward P/E, -3.2% operating margin) versus TTI at $6.20 (21.3x Forward P/E, 7.4% operating margin).

  • Growth vs. Quality Trade-Off: HHS earns the overall head-to-head edge with a stronger Unified Composite Score (61.8/100 BUY vs. TTI 35.2/100 SELL) and 0.49β · 46% Vol risk profile, whereas TTI leads top-line expansion (+9.6% YoY revenue growth, 1.82x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HHS vs TTI
HHS US Equity Head-to-Head Winner
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.84
-4.24% 1D
Market Cap $30.0M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26
TTI NYSE
TETRA Technologies, Inc.
Crude Petroleum & Natural Gas
$6.20
-2.97% 1D
Market Cap $945.5M
TTM Revenue $657M
Forward P/E 21.3x
Beta / 30D Vol 1.44β · 60% Vol
Unified Composite Score
35.2 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.5 · SMA20: $5.85 · SMA50: $5.99

6-Pillar Scorecard Institutional Category Breakdown (HHS 1 – 4 TTI)

Columns: Metric · HHS · TTI
1. Valuation Multiples HHS
Forward P/E 14.3x 21.3x
Trailing P/E 14.3x 91.0x
PEG Ratio 1.19x 1.82x
EV / Revenue 0.3x 1.4x
2. Growth & Scale TTI
Revenue Growth (YoY) -1.7% +9.6%
Earnings Growth (YoY) -90.3% +54.0%
TTM Revenue (USD) $155M $657M
Market Cap $30.0M $945.5M
3. Profitability & Quality TTI
Gross Margin 16.1% 28.8%
Operating Margin -3.2% 7.4%
Net Profit Margin -3.7% 1.4%
Return on Equity (ROE) -30.4% 2.9%
4. Balance Sheet & Cash Flow TTI
Cash Generation (TTM) -$4.5M $87M EBITDA
Cash Flow Margin -2.9% 13.2% EBITDA Mgn
Net Cash / Leverage $17M Net Debt (1.10x D/E) $2.80 Book/Sh · 2.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 57.2% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TTI
OpEx & R&D Intensity 19.3% of Rev ($30M) 21.4% of Rev ($140M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Conglomerates Operator Oil & Gas Equipment & Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HHS (5) vs TTI (5)
Institutional Metric HHS TTI Criterion Row Edge
Market Capitalization
Scale
$30.0M $945.5M Larger Scale TTI
Trailing P/E Ratio
Valuation
14.3x 91.0x Lower Multiple HHS
Forward P/E Ratio
Valuation
14.3x 21.3x Lower Multiple HHS
Revenue Growth (YoY)
Growth
-1.7% +9.6% Higher Growth TTI
Operating Margin (TTM)
Profitability
-3.2% 7.4% Higher Margin TTI
Net Profit Margin
Profitability
-3.7% 1.4% Higher Margin TTI
Return on Equity (ROE)
Capital Efficiency
-30.4% 2.9% Higher ROE TTI
52-Week Range Position
Momentum
69% ($2–$5) 17% ($5–$13) Stronger Trend HHS
Beta / 30D Volatility
Risk Regime
0.49β · 46% Vol 1.44β · 60% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
61.8 / 100 (BUY) 35.2 / 100 (SELL) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
$155M $657M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.1% 28.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.19x PEG · 0.3x EV/Rev 1.82x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.5M ($17M Net Debt (1.10x D/E)) $87M EBITDA ($2.80 Book/Sh · 2.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TTI +27.03 pp
HHS: -10.49% · TTI: +16.54%
3M Horizon HHS +18.55 pp
HHS: -3.76% · TTI: -22.31%
6M Horizon HHS +72.78 pp
HHS: +36.17% · TTI: -36.61%
1Y Horizon HHS +52.18 pp
HHS: +34.74% · TTI: -17.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs TTI. Trailing 12-month operating profitability (HHS -3.2% vs TTI 7.4%) and valuation multiples (HHS 14.3x vs TTI 21.3x Forward P/E) are benchmarked directly in Pillar 4 below.

HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x
TTI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$657M
Gross Margin28.8%
Op. Margin7.4%
ROE / Fwd P/E2.9% · 21.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TTI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 57.2%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TTI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published
TTI Moat Profile Cyclical / Execution-Driven Positioning
Oil & Gas Equipment & Services Operator
Competes within the Oil & Gas Equipment & Services value chain with $945.5M market capitalization and 7.4% operating margin.
OpEx & R&D Reinvestment 21.4% of Rev ($140M)
90D Engineering Disclosures 0 Published

Investor FAQ HHS vs TTI Key Questions & Quantitative Answers

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) captures the overall head-to-head institutional edge over TETRA Technologies, Inc. (TTI) on higher Unified Composite conviction (61.8/100 BUY vs. 35.2/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while TTI wins 4–1 across the 6-pillar growth and valuation breakdown. HHS trades at $3.84 (14.3x Forward P/E, -3.2% operating margin) versus TTI at $6.20 (21.3x Forward P/E, 7.4% operating margin). Growth vs. Quality Trade-Off: HHS earns the overall head-to-head edge with a stronger Unified Composite Score (61.8/100 BUY vs. TTI 35.2/100 SELL) and 0.49β · 46% Vol risk profile, whereas TTI leads top-line expansion (+9.6% YoY revenue growth, 1.82x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

TTI leads the Growth & Scale pillar: HHS posts -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin), compared with TTI at +9.6% YoY revenue growth and +54.0% YoY earnings growth on $657M TTM revenue (28.8% gross margin, 7.4% operating margin). On trailing 12-month operating scale, HHS generates $155M in USD-normalized revenue versus $657M for TTI. In operating R&D and SG&A reinvestment, HHS deploys 19.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus 21.4% of Rev ($140M) (0 disclosures) for TTI.

HHS screens cheaper on headline valuation multiples. HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin), whereas TTI trades at 21.3x Forward P/E, 91.0x Trailing P/E, 1.82x PEG, and 1.4x EV/Revenue (13.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HHS (-30.4% ROE) versus TTI (2.9% ROE) capital efficiency.

In options market volatility and institutional positioning, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk). By comparison, TTI carries 57.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.44β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.